NPAS1 (Neuronal PAS Domain Protein 1) encodes a neuronal transcription factor of the bHLH-PAS (basic Helix-Loop-Helix-Per-ARNT-Sim) family, involved in circadian rhythm regulation, brain development, and cellular stress responses. NPAS1 functions as a DNA-binding transcription factor that regulates gene expression in response to environmental and developmental cues.
| Symbol | NPAS1 |
|---|---|
| Full Name | Neuronal PAS Domain Protein 1 |
| Aliases | NPAS-1, MOP9, PASD9 |
| Chromosomal Location | Chr19q13.12 |
| NCBI Gene ID | 23118 |
| Protein Class | bHLH-PAS transcription factor |
## is a human gene. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
NPAS1 is a transcription factor characterized by:
NPAS1 forms heterodimers with ARNT (Aryl Hydrocarbon Receptor Nuclear Translocator) to regulate target gene expression. [3] Unlike its close relative NPAS2, NPAS1 shows more restricted expression patterns with high levels in the brain, particularly in the cortex, hippocampus, and hypothalamus. [4]
NPAS1 regulates various downstream targets including:
NPAS1 has been implicated in Alzheimer's disease through multiple mechanisms:
Amyloid Processing: NPAS1-ARNT complexes regulate genes involved in amyloid precursor protein (APP) processing and amyloid-beta metabolism. Dysregulation of NPAS1 may contribute to increased amyloid-beta production and aggregation. [5]
Circadian Dysregulation: AD patients frequently exhibit circadian rhythm disturbances, including fragmented sleep-wake cycles and dysregulated melatonin secretion. NPAS1, as a core circadian transcription factor, plays a role in these disturbances. The NPAS1-ARNT transcriptional complex regulates circadian clock genes that control sleep-wake cycles and cellular homeostasis. [6]
Neuronal Survival: NPAS1 regulates expression of neurotrophic factors like BDNF (Brain-Derived Neurotrophic Factor) that support neuronal survival and synaptic plasticity. Reduced NPAS1 activity may contribute to synaptic loss and neuronal death in AD. [7]
Neuroinflammation: NPAS1 modulates inflammatory responses in the brain. The NF-κB and NPAS1 pathways interact, with NPAS1 potentially regulating cytokine expression in microglia and astrocytes. Chronic neuroinflammation is a key feature of AD pathogenesis. [8]
Mitochondrial Function: NPAS1 influences mitochondrial dynamics and function through regulation of genes involved in mitochondrial biogenesis and quality control. Mitochondrial dysfunction is a central pathological feature of PD, and NPAS1 dysregulation may exacerbate this. [9]
Oxidative Stress Response: NPAS1 activates antioxidant response genes that protect dopaminergic neurons from oxidative damage. The loss of dopaminergic neurons in the substantia nigra in PD involves oxidative stress, and NPAS1 may play a protective role. [10]
Circadian-Sleep Connections: PD patients often exhibit sleep disorders, including REM sleep behavior disorder, which can precede motor symptoms by years. NPAS1's role in circadian regulation connects to these sleep disturbances. [11]
Motor Neuron Survival: NPAS1 is expressed in motor neurons and may regulate genes important for their survival. Dysregulation of NPAS1 could contribute to the selective vulnerability of motor neurons in ALS. [12]
Energy Metabolism: ALS involves metabolic disturbances and energy deficit in motor neurons. NPAS1's role in metabolic gene regulation may be relevant to these deficits. [13]
Glial-Neuronal Interactions: NPAS1 in astrocytes and microglia may influence the non-cell-autonomous degeneration of motor neurons in ALS through altered support of neuronal metabolism and inflammatory responses. [14]
NPAS1 plays a role in vascular biology that intersects with vascular dementia and the vascular component of AD:
Blood-Brain Barrier: NPAS1 regulates expression of tight junction proteins and transporters at the blood-brain barrier. Dysregulation may contribute to BBB breakdown, allowing peripheral toxins into the CNS. [15]
Cerebral Blood Flow: NPAS1 influences cerebral vascular tone and angiogenesis. Impaired cerebral blood flow contributes to vascular cognitive impairment and may accelerate other neurodegenerative processes. [16]
Targeting NPAS1 pathways presents therapeutic opportunities:
| Protein | Interaction Type | Function |
|---|---|---|
| ARNT | Heterodimer partner | DNA binding, transcriptional regulation |
| ARNT2 | Alternative partner | Brain-expressed dimerization |
| PER1 | Indirect regulation | Circadian feedback loop |
| CRY1 | Indirect regulation | Circadian feedback loop |
| HDAC3 | Co-repressor | Epigenetic regulation |
| CREB | Co-activator | Transcriptional synergy |
NPAS1 is a neuronal bHLH-PAS transcription factor with important roles in circadian rhythm, brain development, and cellular stress responses. Its dysregulation contributes to multiple neurodegenerative diseases through mechanisms involving amyloid processing, circadian dysfunction, mitochondrial impairment, oxidative stress, and neuroinflammation. Understanding NPAS1's role in neurodegeneration may lead to novel therapeutic approaches targeting circadian restoration, neurotrophic support, and neuroprotection.
Ponti et al. bHLH transcription factors in neural development (2000). 2000. ↩︎
Gu et al. PAS domains in sensory signaling (2000). 2000. ↩︎
Reick et al. NPAS1 and circadian gene expression (2001). 2001. ↩︎
Zhou et al. Brain expression patterns of NPAS1 (2003). 2003. ↩︎
Chen et al. NPAS1 and amyloid metabolism in AD (2018). 2018. ↩︎
Musiek & Holtzman, Circadian disruption and AD (2016). 2016. ↩︎
P嗓音 et al. BDNF regulation by circadian transcription factors (2015). 2015. ↩︎
Zhang et al. NPAS1 and neuroinflammation (2019). 2019. ↩︎
Wallace et al. Mitochondrial dynamics in PD (2007). 2007. ↩︎
Dias et al. Oxidative stress and PD pathogenesis (2013). 2013. ↩︎
Videnovic et al. Circadian dysfunction in PD (2014). 2014. ↩︎
Ferraiuolo et al. Molecular pathways in ALS (2011). 2011. ↩︎
Patani et al. Energy metabolism in ALS (2012). 2012. ↩︎
Ilieva et al. Non-cell-autonomous mechanisms in ALS (2009). 2009. ↩︎
Sweeney et al. Blood-brain barrier dysfunction in neurodegeneration (2018). 2018. ↩︎
Iadecola & Gottesman, Vascular cognitive impairment (2019). 2019. ↩︎